With the continuous refinement of therapeutic measures, the survival rate of tumor patients has been improving year by year, while cardiovascular complications related to cancer therapy have become increasingly prominent. Exploring the mechanism and prevention strategy of cancer therapy-related cardiovascular toxicity (CTR-CVT) remains one of the research hotspots in the field of Cardio-Oncology in recent years. Cardiotoxicity of anticancer drugs involves heart failure, myocarditis, hypertension, arrhythmias and vascular toxicity, mechanistically related to vascular endothelial dysfunction, ferroptosis, mitochondrial dysfunction and oxidative stress. To address the cardiotoxicity induced by different anticancer drugs, various therapeutic measures have been put in place, such as reducing the accumulation of anticancer drugs, shifting to drugs with less cardiotoxicity, using cardioprotective drugs, and early detection. Due to the very limited treatments available to ameliorate anticancer drugs-induced cardiotoxicity, a few innovations are being shifted from animal studies to human studies. Examples include mitochondrial transplantation. Mitochondrial transplantation has been proven to be effective in in vivo and in vitro experiments. Several recent studies have demonstrated that intercellular mitochondrial transfer can ameliorate doxorubicin(DOX)-induced cardiotoxicity, laying the foundation for innovative therapies in anticancer drugs-induced cardiotoxicity. In this review, we will discuss the current status of anticancer drugs-induced cardiotoxicity in terms of the pathogenesis and treatment, with a focus on mitochondrial transplantation, and we hope that this review will bring some inspiration to you.
Background: The incidence of coronary heart disease (CHD) in premenopausal women is significantly lower than that of men of the same age, suggesting protective roles of estrogen for the cardiovascular system against CHD. This study aimed to confirm the protective effect of estrogen on myocardium during myocardial ischemia/reperfusion (MI/R) injury and explore the underlying mechanisms. Methods: Neonatal rat cardiomyocytes and Sprague–Dawley rats were used in this study. Different groups were treated by bilateral ovariectomy, 17β-estradiol (E2), adenoviral infection, or siRNA transfection. The expression of sarcoplasmic reticulum Ca2+ ATPase pump (SERCA2a) and endoplasmic reticulum (ER) stress-related proteins were measured in each group to examine the effect of different E2 levels and determine the relationship between SERCA2a and ER stress. The cell apoptosis, myocardial infarction size, levels of apoptosis and serum cardiac troponin I, ejection fraction, calcium transient, and morphology changes of the myocardium and ER were examined to verify the effects of E2 on the myocardium. Results: Bilateral ovariectomy resulted in reduced SERCA2a levels and more severe MI/R injury. E2 treatment increased SERCA2a expression. Both E2 treatment and exogenous SERCA2a overexpression decreased levels of ER stress-related proteins and alleviated myocardial damage. In contrast, SERCA2a knockdown exacerbated ER stress and myocardial damage. Addition of E2 after SERCA2a knockdown did not effectively inhibit ER stress or reduce myocardial injury. Conclusions: Our data demonstrate that estrogen inhibits ER stress and attenuates MI/R injury by upregulating SERCA2a. These results provide a new potential target for therapeutic intervention and drug discovery in CHD.
17 April 2026 in Frontiers in Cardiovascular Medicine
Background: Recent studies have demonstrated that patients with ST-segment elevation myocardial infarction (STEMI) without standard modifiable cardiovascular risk factors (SMuRF-less) experience worse in-hospital outcomes than those with standard modifiable cardiovascular risk factors (SMuRFs); however, the role of a critical pathological mechanism coronary microvascular dysfunction (CMVD) in this context remains unclear. Objectives: To investigate whether CMVD mediates the association between SMuRF-less status and in-hospital major adverse cardiovascular events (MACE). Methods: A total of 1,027 STEMI patients undergoing percutaneous coronary intervention (PCI) were enrolled and classified into a SMuRFs group (≥1 SMuRF, n = 806) and a SMuRF-less group (no SMuRFs, n = 221). In-hospital MACE and post-procedural coronary angiography–derived index of microcirculatory resistance (caIMR) were compared between groups. Mediation analysis was performed to assess the mediating effect of post-procedural caIMR on the association between SMuRF-less status and in-hospital outcomes. Results: The incidence of in-hospital MACE was significantly higher in the SMuRF-less group than in the SMuRFs group (15.3% vs. 7.0%, P < 0.001). After adjustment for potential confounders, mediation analysis demonstrated that post-procedural caIMR partially mediated the association between SMuRF-less status and increased in-hospital MACE risk ( β = 0.284, 95% bootstrap CI: 0.101–0.498). Conclusion: Elevated post-procedural caIMR, as a quantitative surrogate of CMVD, independently predicted in-hospital MACE and partially mediated the association between SMuRF-less status and adverse in-hospital outcomes in STEMI patients.